Efficacy and Safety of Potent P2Y12 Inhibitors vs. Clopidogrel in Elderly ACS Patients

0
0
0

Efficacy and Safety of Potent P2Y12 Inhibitors vs. Clopidogrel in Elderly Patients with Acute Coronary Syndrome

Acute coronary syndrome (ACS) remains a leading cause of morbidity and mortality in elderly populations. Current guidelines recommend dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 inhibitor, such as clopidogrel, prasugrel, or ticagrelor, for ACS management. However, the efficacy and safety of potent P2Y12 inhibitors (prasugrel and ticagrelor) compared to clopidogrel in elderly patients, particularly those aged ≥75 years, remain understudied. This meta-analysis evaluates clinical outcomes in elderly ACS patients receiving potent P2Y12 inhibitors versus clopidogrel, addressing ischemic benefits, bleeding risks, and the impact of dose adjustments.

Study Design and Methodology

The analysis included seven randomized controlled trials (RCTs) published between January 2000 and December 2019, encompassing 8,848 elderly ACS patients (≥65 years). Data sources included PubMed, Cochrane Library, Web of Science, and EMBASE. The primary outcomes were major adverse cardiovascular events (MACEs), all-cause mortality, and major bleeding. Risk ratios (RRs) with 95% confidence intervals (CIs) were calculated using Stata 12.0. Subgroup analyses focused on age stratification (≥65 vs. ≥75 years) and dosing regimens (standard vs. reduced maintenance doses of prasugrel).

Among the included studies, 5,648 patients (63.8%) received prasugrel (43.4% at reduced doses <10 mg), while others received ticagrelor or clopidogrel. All trials were deemed high-quality, with no significant heterogeneity (I² = 0–42.3%) for most outcomes.

Clinical Outcomes

Ischemic Efficacy

The pooled analysis revealed no significant difference in MACEs between potent P2Y12 inhibitors and clopidogrel in patients ≥65 years (RR = 0.95, 95% CI: 0.86–1.05; P = 0.844) or ≥75 years (RR = 1.38, 95% CI: -0.83–3.60; P = 0.034), though the latter subgroup exhibited high heterogeneity (I² = 77.7%). Subgroup analyses further demonstrated:

  • Ticagrelor vs. Clopidogrel: No significant reduction in MACEs (RR = 0.81, 95% CI: 0.30–1.31; P = 0.026).
  • Reduced-Dose Prasugrel vs. Clopidogrel: Comparable MACE rates (RR = 1.02, 95% CI: 0.86–1.18; P = 0.921).

For all-cause mortality, potent P2Y12 inhibitors showed a modest but statistically significant reduction (RR = 0.82, 95% CI: 0.66–0.97; P = 0.215; I² = 31%).

Bleeding Risks

Potent P2Y12 inhibitors were associated with a 25% increased risk of major bleeding compared to clopidogrel (RR = 1.25, 95% CI: 0.99–1.51; P = 0.890). Subgroup findings included:

  • Age ≥65 Years: RR = 1.21 (95% CI: 0.94–1.49).
  • Age ≥75 Years: RR = 1.58 (95% CI: 0.77–2.39).
  • Reduced-Dose Prasugrel: No significant bleeding risk difference vs. clopidogrel (RR = 1.23, 95% CI: 0.68–1.78; P = 0.422).

Key Implications

  1. Ischemic Protection: Potent P2Y12 inhibitors did not outperform clopidogrel in reducing MACEs, regardless of age or dosing strategy. However, they demonstrated a borderline reduction in all-cause mortality, suggesting potential survival benefits in select populations.
  2. Dosing Considerations: Reduced-dose prasugrel (<10 mg) showed comparable efficacy and safety to clopidogrel, aligning with expert consensus cautioning against standard-dose prasugrel in high-bleeding-risk elderly patients.
  3. Bleeding Trade-offs: The increased bleeding tendency with potent agents underscores the need for individualized risk stratification. While reduced-dose prasugrel did not significantly elevate bleeding risk, the overall trend warrants caution.

Limitations and Future Directions

The study’s limitations include heterogeneity in the definition of “potent P2Y12 inhibitors,” as prasugrel and ticagrelor have distinct pharmacokinetic profiles. Only 17.2% of patients received ticagrelor, limiting generalizability. Additionally, the analysis lacked granular data on bleeding severity, comorbid conditions, or drug interactions.

Future research should prioritize RCTs comparing reduced-dose prasugrel and ticagrelor head-to-head in elderly cohorts. Larger sample sizes and extended follow-up periods are needed to validate mortality benefits and optimize dosing protocols.

Conclusion

In elderly ACS patients, potent P2Y12 inhibitors offer similar ischemic protection to clopidogrel but carry a higher bleeding risk. Reduced-dose prasugrel emerges as a viable alternative, balancing efficacy and safety. Clinicians must weigh thrombotic versus bleeding risks when selecting DAPT regimens, particularly in frail or high-bleeding-risk individuals.

doi.org/10.1097/CM9.0000000000001119

Was this helpful?

0 / 0